LPCN News 7.50 Lipocine Inc (LPCN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lipocine Inc (LPCN) 7.50 $LPCN

Nasdaq stocks posting largest percentage increases
AP - Mon Mar 24, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Lipocine to Begin Trading on the NASDAQ Capital Market
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. The Company's common stock is expected to begin trading on the NASDAQ Capital Market on or about March 21, 2014, under its current trading symbol "LPCN".

Lipocine to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 1:00 p.m. ET.

Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
GlobeNewswire - Mon Feb 10, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR" pivotal Phase 3 clinical study. The trial is designed to evaluate the safety and efficacy of LPCN 1021, an oral testosterone replacement therapy, in hypogonadal men with low testosterone (Low T; www.lowtstudy.com). Approximately 300 patients are expected to be enrolled in multiple sites in the United States. The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA" filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015.

Lipocine to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.

Lipocine Announces New Appointments to Its Board of Directors
GlobeNewswire - Tue Jan 07, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. Dr. Mahesh Patel, Lipocine President and Chief Executive Officer, has assumed the position of Chairman of the Board and Dr. Higuchi will serve as the Company's Chief Scientific Advisor.

Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
GlobeNewswire - Fri Dec 13, 3:30PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013.

Lipocine Inc. Announces Exercise and Closing of Over-Allotment Option
GlobeNewswire - Fri Dec 06, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering have fully exercised their option to purchase an additional 223,800 shares of Lipocine common stock at a price of $8.25 per share, for additional gross proceeds of approximately $1.8 million. The gross proceeds to Lipocine from the offering, including the exercise of the over-allotment option, will be approximately $14.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine.

Lipocine Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Nov 27, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public offering of 1,492,000 shares of its common stock at a price to the public of $8.25 per share. The gross proceeds from this offering to Lipocine are expected to be approximately $12.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine. Lipocine has granted the underwriters a 30-day option to purchase up to an aggregate of 223,800 additional shares of common stock. The offering is expected to close on or about November 29, 2013, subject to customary closing conditions. Lipocine expects to use the net proceeds of this offering to conduct clinical trials for its lead product candidate LPCN 1021 and other product candidates and the balance for working capital and general corporate purposes.

Market Research: Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/34w87h/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013" report to their offering. 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder. Scope - A snapshot of the global therapeutic scenario for Female Hypoactive Sexual Desire Disorder. - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NexMed, Inc. Palatin Technologies, Inc. ANI Pharmaceuticals, Inc. Fabre-Kramer Pharmaceuticals, Inc. Lipocine Inc. For more information visit http://www.researchandmarkets.com/research/34...hypoactive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lipocine Inc. Appoints Morgan Brown as Executive Vice President and Chief Financial Officer
Business Wire - Mon Sep 16, 7:00AM CDT
Lipocine Inc. ("Lipocine" (OTCQB/OTCBB: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer ("CFO" . Mr. Brown has more than 20 years of financial and accounting experience, including over 13 years in financial management of life science companies.

Male Hypogonadism - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4f82bh/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2013" report to their offering. 'Male Hypogonadism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Hypogonadism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Hypogonadism. Scope - A snapshot of the global therapeutic scenario for Male Hypogonadism. - A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Hypogonadism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Endo Pharmaceuticals Holdings Inc. Merck & Co., Inc. Novartis AG Clarus Therapeutics, Inc. Ascend Therapeutics, Inc. Repros Therapeutics Inc. M et P Pharma AG APTYS Pharmaceuticals Pantarhei Bioscience BV Monosol Rx, LLC Lipocine Inc. Diurnal Ltd For more information visit http://www.researchandmarkets.com/research/4f...pogonadism About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 102

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 76

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 327

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth

Updated Category News Views 269

Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...

Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO

Updated Category News Views 183

Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...

Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market

Updated Category News Views 302

Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...

Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates

Updated Category News Views 170

Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...

Continue Reading